With the advent of next-generation sequencing (NGS) technologies, germline testing for hereditary BC and ovarian cancer (OC) will be extended beyond the analysis of the BRCA1 and BRCA2 genes (Desmond et al., 2015). This evidence concerns the gene BRCA1 and breast cancer.